Mirvetuximab soravtansine-gynx inotenderwa neUSFDA yeFRα yakanaka, inodzivirira platinamu epithelial ovarian, fallopian tube, kana primary peritoneal cancer.
March 2024: The Food and Drug Administration has granted approval for mirvetuximab soravtansine-gynx (Elahere, ImmunoGen, Inc. [now a part of AbbVie]) to be used in adult patients with FRα positive, platinum-resistant epithelial ..
Clinical trials
MESO-CAR T Masero Therapy yeKudzokerazve uye Refractory Epithelial Ovarian Cancer
March 2023: Brief Summary: The purpose of this clinical trial is to find out if anti-MESO antigen receptor CAR T-cell therapy can be used to treat epithelial ovarian cancer that has come back or stopped responding to other..
mirvetuximab soravtansine-gyn
Mirvetuximab soravtansine-gynx inopiwa kukurumidza kubvumidzwa kweFRα yakanaka, platinamu-inodzivirira epithelial ovarian, fallopian chubhu, kana peritoneal cancer.
Mbudzi 2022: Kune varwere vakuru vakamboita imwe kusvika kune matatu yekutanga systemic kurapwa regimens uye vane folate receptor alpha (FR) yakanaka, platinamu-resistant epithelial ovarian, fallopian chubhu, kana primary peritoneal cancer, F.
Lancet, Mekinist, Tamoxifen, Trametinib
Kurapwa kutsva kwakaratidzwa kune yakaderera giredhi uye serous ovarian cancer
Chivabvu 2022: Trametinib inogona kuve chiyero chitsva chekutarisira inodzokororwa, yakaderera-giredhi serous ovarian cancer (Mekinist). Zvinoenderana nezvakawanikwa muongororo yakaburitswa muna Kukadzi 2022 chinyorwa cheThe Lancet, trametinib yakakunda ese ari maviri chemotherapy.
Cytalux, NCT03180307, pafolacianine, Target Laboratories
Pafolacianine inobvumirwa kuti ione zvirwere zvegomarara reovarian
Jan 2022: Pafolacianine (Cytalux, On Target Laboratories, LLC), an optical imaging agent, akapihwa rezinesi neFood and Drug Administration yevarwere vakuru vane ovarian cancer semubatsiri wekuonana.
Niraparib
Niraparib inowana mhedzisiro inoshamisa yeiyo ovari uye kenza yemazamu
Kenza yemuzamu & ovariKana iwe uri zamu uye ovari kenza murwere, iwe unozoona kuti uri kenza ye BRCA1 / 2 mutation mushure mekupasa iyo genetiki bvunzo, uye hupenyu hwako hunoponeswa. Zvinoenderana neGlobal Oncolog ..
Acalabrutunib, Avelumab, CART kurapa, Dabrafanib, Kymriah, Dzazvino zvinodhaka, Midostaurin, Niraparib, Pembrolizumab, Tecartus, Tisagenlecleucel, Trametinib, USFDA
Dzazvino mishonga yekurapa kenza
Chikunguru 2021: Tarisa uone mishonga ichangoburwa mukurapa cancer. Gore rega rega, mushure mekuongorora miedzo uye zvimwe zvakakosha, USFDA inobvumidza mishonga, uye nekudaro varwere vegomarara vanogona kutenda kuti kurapwa kwave pedyo. ..